Mood Stabilizers: How They Work, What to Expect, and How to Talk to Your Prescriber

The term “mood stabilizer” is a functional category, not a pharmacological class. What the medications in this group share is not a common mechanism — lithium, valproate, lamotrigine, and carbamazepine work through very different pathways — but a common clinical effect: they reduce the tendency of mood to cycle between extreme states. The target is the cycling mechanism itself, not the mood state at any given moment.

Neurologically, different mood stabilizers work through different mechanisms. Lithium affects second messenger systems (the inositol pathway, GSK-3) and has neuroprotective effects not seen with other agents. Valproate and lamotrigine modulate sodium channels, which reduces the rapid firing of neurons associated with cycling mood states. Carbamazepine is also a sodium channel blocker. Some agents (valproate) enhance GABA (the brain's primary inhibitory neurotransmitter) and reduce glutamate (excitatory); these effects contribute to their anti-manic properties.

Who are they prescribed for? Mood stabilizers are first-line treatment for bipolar I disorder, bipolar II disorder, and schizoaffective disorder (bipolar type). They are also used off-label for treatment-resistant depression (as augmentation), borderline personality disorder (particularly lamotrigine for emotional dysregulation), and sometimes for impulsive aggression in other contexts. Each of these uses has a different evidence base and involves a different clinical calculus.

These are the medications most commonly used in this category. Each has a distinct profile of uses, monitoring requirements, and risks. This table is a starting point — not a substitute for a conversation with your prescriber about which is right for your specific situation.

Quetiapine is technically an atypical antipsychotic, not a classic mood stabilizer, but it has FDA approval for bipolar depression, acute mania, and bipolar maintenance — and it is commonly used in this role. The boundaries between medication categories are more porous in clinical practice than they appear in textbooks.

One of the most important things to understand about mood stabilizers is that their timelines are genuinely different from antidepressants — and from each other. Stopping early because “it's not working yet” is one of the most common reasons treatment fails.

Lithium

For acute mania, lithium typically begins to show effect within 1–3 weeks once a therapeutic level is reached. For prophylaxis — preventing future episodes — the full benefit takes 3–6 months. Lithium's anti-suicide effects, which are distinct from its mood-stabilizing effects, also develop over time. Stopping lithium abruptly is particularly dangerous: there is a rebound effect that can trigger a severe manic or mixed episode within weeks.

Lamotrigine

Lamotrigine requires a very slow titration — typically starting at 25 mg and increasing by 25 mg every two weeks — specifically because rapid escalation dramatically increases the risk of Stevens-Johnson syndrome (SJS), a rare but potentially serious skin reaction. This slow titration means patients often do not reach a therapeutic dose until 6–8 weeks in. Expecting it to “work” before a full therapeutic dose has been reached sets up early discontinuation. The titration schedule is not optional — it is a safety protocol.

Valproate

Valproate reaches therapeutic levels faster than lithium or lamotrigine, and can be loaded at higher doses for acute mania in inpatient settings. Outpatient titration is more gradual. Anti-manic effects are often seen within 1–2 weeks. Like lithium, stopping valproate abruptly can cause rapid cycling rebound.

The general principle across all mood stabilizers: these are medications that require patience during initiation and commitment during maintenance. The recurrence risk after stopping is real and documented — it is part of the risk-benefit conversation, not a footnote.

Every mood stabilizer has a side effect profile. Understanding them in advance helps you distinguish manageable effects from signs that warrant a call — or an ER visit.

Lithium

• Fine hand tremor — very common; often improves over time or with propranolol
• Polyuria and polydipsia (increased urination and thirst) — affects up to 40% of patients; manageable, but tell your prescriber
• Cognitive dulling / word-finding difficulty — often dose-related; worth a level check if new or worsening
• Weight gain — modest; partly related to increased fluid intake; dietary awareness helps

Valproate

• Weight gain — significant for many patients; the most common reason for non-adherence
• Hair loss — often temporary; zinc and selenium supplements may help (ask your prescriber before starting)
• Cognitive effects — sedation, word-finding difficulty; more pronounced at higher doses
• Teratogenicity — among the highest risks of any psychiatric medication in pregnancy; see below

Lamotrigine

• Headache — common in early weeks; usually resolves
• Rash — the warning sign to know — a benign rash can occur during titration; Stevens-Johnson syndrome is rare (<0.1%) but serious. Any rash involving mucous membranes (mouth, eyes, genitals), fever, or skin peeling warrants immediate ER evaluation — do not wait.

Carbamazepine

• Dizziness and sedation — particularly at initiation; usually improves
• CYP interactions — carbamazepine strongly induces liver enzymes, meaning it can dramatically reduce the effectiveness of other medications, including hormonal contraceptives. This is a major prescribing consideration. Tell your prescriber every medication and supplement you take.

When to call your prescriber vs. go to the ER

Call your prescriber: new or worsening tremor, increased urination, hair loss, mild rash without systemic symptoms, weight changes, cognitive dulling.

Go to the ER: confusion or slurred speech on lithium (toxicity); rash with fever, blistering, or mucous membrane involvement on lamotrigine (possible SJS); severe vomiting or diarrhea on lithium (dehydration + toxicity risk); any signs of lithium toxicity including coarse tremor, cognitive slowing, or incoordination.

Pregnancy planning is one of the most consequential conversations in psychiatric prescribing — and it is important to have it proactively, not reactively. The risks are not uniform across mood stabilizers, and neither is the risk of stopping them.

Valproate — generally avoid in pregnancy

Valproate carries the highest teratogen risk of any commonly prescribed psychiatric medication. It is associated with neural tube defects (spina bifida), heart defects, cleft palate, and — critically — long-term cognitive effects in the child, including lower IQ and higher rates of autism spectrum disorder. The cognitive effects appear dose-dependent and are not prevented by folate supplementation alone. For most people with reproductive potential, valproate should be avoided if an alternative can provide adequate mood stabilization. This is a strong clinical consensus, not a minority position.

Lithium — lower risk than previously thought, but real

Earlier estimates of Ebstein's anomaly (a cardiac malformation) risk from lithium in the first trimester were significantly overstated due to publication bias. More recent registry data suggests the absolute risk increase is small — approximately 1–2 additional cases per 1,000 exposures. Lithium also requires dose adjustment during pregnancy (volume of distribution increases) and careful monitoring postpartum (lithium levels can spike rapidly after delivery as fluid shifts). Stopping lithium in pregnancy is not automatically safer — untreated bipolar disorder carries its own serious risks for both parent and child.

Lamotrigine — considered relatively safer

Lamotrigine has more favorable pregnancy data than lithium or valproate for structural birth defects at typical doses. However, lamotrigine levels drop significantly during pregnancy (estrogen increases its clearance), often requiring dose increases during pregnancy and dose reductions postpartum. If you become pregnant on lamotrigine, this needs close monitoring — the level change can be clinically significant.

Being an active participant in your treatment means bringing specific questions — not just receiving a prescription. These are the questions that make the most difference in mood stabilizer treatment.

• “Why this medication vs. the others?” — Prescribers have reasons for their choices (your symptom pattern, your history, drug interactions, your reproductive plans). Asking this helps you understand the reasoning and catch cases where an important factor was overlooked.
• “What monitoring do I need, and how often?” — The monitoring requirements differ dramatically: lithium requires blood levels, kidney, and thyroid; valproate requires levels, liver function, and CBC; lamotrigine requires no routine levels but does require rash awareness. Know your specific schedule.
• “What happens if I miss a dose?” — This answer varies by medication. For lithium, missing a dose is not usually a crisis; doubling up is. For lamotrigine, missing doses increases SJS risk (the titration logic applies to maintenance as well). For valproate, a single missed dose is generally less dangerous than abrupt discontinuation.
• “Are there interactions with my other medications or supplements?” — Carbamazepine has numerous clinically significant interactions. Lithium interacts with NSAIDs, ACE inhibitors, and diuretics. Valproate inhibits several liver enzymes. Bring a complete medication list — including over-the-counter and supplements — to every appointment.
• “What are the signs of toxicity I should know?” — For lithium specifically, you should be able to list the early signs of toxicity before you leave the office. For lamotrigine, you should know what a concerning rash looks like and what to do about it.
• “How long do I need to stay on this?” — The evidence increasingly supports long-term maintenance for bipolar disorder; recurrence risk is real and documented. But this is a conversation, not a directive — and it should include your input about what is tolerable and sustainable for you.

For more detail on lithium monitoring specifically, see our Lithium Monitoring guide. For the broader picture on bipolar disorder and medication decisions, see Bipolar Disorder & Medication.